


CO.DON AG

Information on shares

We are a biopharmaceutical company and manufacturer of cell transplants. Our focus is on the development and manufacture of cell therapies for the joint-preserving, minimally invasive treatment of articular cartilage defects using only the body’s own cartilage cells. CO.DON’s method is currently used in over 200 clinics and more than 17,000 patients have already been treated. In July, CO.DON received EU marketing authorisations for its product. At its site in Leipzig CO.DON has built one of the largest plants for the industrial-scale production of human cells.



Executive Board

Tilmann Bur

born in 1964
Board Member since 2019

Tilmann Bur is an internationally experienced sales and marketing manager. With over 20 years’ experience he worked in professional relationship management with decision-makers in orthopedic and surgical clinics in particular, as well as in setting up and managing national and international sales organizations and distribution networks.

Supervisory Board

- **Thomas Hans Stählin**
Chairman
- **Prof. Dr. Barbara Sickmüller**
Vice Chairwoman
- **Prof. Hans-Jörg Bullinger**
Member

Key Capital Market Data

Stock exchange:	Frankfurt am Main
Trading segment:	General Standard
Security identification number:	A3E5C0 A3E5C1
ISIN:	DE000A3E5C08 DE000A3E5C16
Initial public offering:	February 14, 2001
Financial year:	Calendar year
Share type:	Ordinary bearer share with no par value
Actual number of shares:	26,723,358

Shareholder Structure (as announced)

Bauerfeind Beteiligungsgesellschaft mbH (BBG)	54,22 %
BBJ Beteiligungsgesellschaft mbH (BBJ)	4,22 %
Free float	41,56 %

Contact Investor Relations

Matthias Meißner
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)341 99 190 330
E: ir@codon.de